Ovarian cancer risk in relation to medical visits, pelvic examinations and type of health care provider

CMAJ. Canadian Medical Association Journal

Volumn 176, Issue 7, 2007, Pages 941-947

  Abenhaim, Haim A ^a,d   Titus Ernstoff, Linda ^b   Cramer, Daniel W ^a,c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b NORRIS COTTON CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER GRADING; CANCER RISK; CONTROLLED STUDY; FEMALE; HEALTH CARE PERSONNEL; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PELVIS EXENTERATION; POSTMENOPAUSE;

EID: 34147134543     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.060697     Document Type: Article

References (33)

1. American Cancer Society. Cancer facts and figures 2007. Atlanta: American Cancer Society; 2007. Available: www.cancer.org/docroot/STT/content/ STT_IX_Cancer_ Facts_Figures_2007.asp (accessed 2007 Feb 26).
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55: 10-30.
3. Szucs TD, Wyss P, Dedes KJ. Cost-effectiveness studies in ovarian cancer. Int J Gynecol Cancer 2003;13(Suppl 2):212-9.
4. Menon U, Jacobs I. Screening for ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2002;16:469-82.
5. Sato S, Yokoyama Y, Sakamoto T, et al. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer 2000;89:582-8.
6. Van Nagell JR Jr, DePriest PD, Reedy MB, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350-6.
7. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
8. Jacobs I, Davies AP, Bridges J, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993; 306:1030-4.
9. American College of Obstetricians and Gynecologists. ACOG committee opinion number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002;100:1413-6.
10. Brenner H, Hakulinen T. Period estimates of cancer patient survival are more up-to-date than complete estimates even at comparable levels of precision. J Clin Epidemiol 2006;59:570-5.
11. Silcocks PB, Robinson D. Completeness of ascertainment by cancer registries: putting bounds on the number of missing cases. J Public Health (Oxf) 2004;26:161-7.
12. Bohlke K, Harlow BL, Cramer DW, et al. Evaluation of a population roster as a source of population controls: the Massachusetts Resident Lists. Am J Epidemiol 1999;150:354-8.
13. Lynch CF, Logsden-Sackett N, Edwards SL, et al. The driver's license list as a population-based sampling frame in Iowa. Am J Public Health 1994;84:469-72.
14. Cramer DW, Harlow BL, Titus-Ernstoff L, et al. Over-the-counter analgesics and risk of ovarian cancer. Lancet 1998;351:104-7.
15. Salganicoff A, Beckerman JZ, Wyn R, et al. Women's health in the United States: Health coverage and access to care. Menlo Park (CA): Henry J. Kaiser Family Foundation; 2002. Available: www.kff.org/womenshealth/loader.cfm? url=/commonspot/security/getfile.cfm&PageID=14153 (accessed 2007 Jan 31).
16. Marchbanks PA, Wilson H, Bastos E, et al. Cigarette smoking and epithelial ovarian cancer by histologic type. Obstet Gynecol 2000;95:255-60.
17. Cramer DW. Perineal talc exposure and subsequent epithelial ovarian cancer: a case-control study. Obstet Gynecol 1999;94:160-1.
18. Gertig DM, Hunter DJ, Cramer DW, et al. Prospective study of talc use and ovarian cancer. J Natl Cancer Inst 2000;92:249-52.
19. Kuper H, Cramer DW, Titus-Ernstoff L. Risk of ovarian cancer in the United States in relation to anthropometric measures: Does the association depend on menopausal status? Cancer Causes Control 2002;13:455-63.
20. Glud E, Kjaer SK, Thomsen BL, et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 2004;164:2253-9.
21. Bakken K, Alsaker E, Eggen AE, et al. Hormone replacement therapy and incidence of hormone-dependent cancers in the Norwegian women and cancer study. Int J Cancer 2004;112:130-4.
22. Green A, Purdie D, Bain C, et al. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer 1997; 71:948-51.
23. Kjaer SK, Mellemkjaer L, Brinton LA, et al. Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65 000 sterilized women. Int J Epidemiol 2004;33:596-602.
24. Siskind V, Green A, Bain C, et al. Beyond ovulation: oral contraceptives and epithelial ovarian cancer [see comment]. Epidemiology 2000;11:106-10.
25. Bosetti C, Negri E, Trichopoulos D, et al. Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 2002;101:262-5.
26. Fleischauer AT, Olson SH, Mignone L, et al. Dietary antioxidants, supplements, and risk of epithelial ovarian cancer. Nutr Cancer 2001;40:92-8.
27. Cramer DW, Kuper H, Harlow BL, et al. Carotenoids, antioxidants and ovarian cancer risk in pre- and postmenopausal women. Int J Cancer 2001;94:128-34.
28. Wong WW, Dimitroulakos J, Minden MD, et al. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19.
29. Splichal JE, Stamm JA, Ornstein DL. The statins: multifunctional antithrombotic and antineoplastic drugs. Semin Thromb Hemost 2003;29:259-74.
30. Risch HA, Marrett LD, Jain M, et al. Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 1996; 144:363-72.
31. Brinton LA, Gridley G, Persson I, et al. Cancer risk after a hospital discharge diagnosis of endometriosis [see comment]. Am J Obstet Gynecol 1997;176:572-9.
32. Borgfeldt C, Andolf E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 2004;83:395-400.
33. Puls LE, Powell DE, DePriest PD, et al. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma. Gynecol Oncol 1992;47:53-7.